1. Home
  2. TXMD vs FEMY Comparison

TXMD vs FEMY Comparison

Compare TXMD & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$1.85

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

FEMY

Femasys Inc.

BUY

Current Price

$1.49

Market Cap

22.4M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
TXMD
FEMY
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.4M
22.4M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
TXMD
FEMY
Price
$1.85
$1.49
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $14.33
AVG Volume (30 Days)
18.2K
★ 99.6K
Earning Date
11-11-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 73.68
44.71
EPS
★ 0.02
N/A
Revenue
$1,761,000.00
★ $2,293,313.00
Revenue This Year
$207.74
N/A
Revenue Next Year
$2.15
$328.45
P/E Ratio
$92.50
★ N/A
Revenue Growth
35.25
★ 40.77
52 Week Low
$1.11
$0.29
52 Week High
$2.95
$6.29

Technical Indicators

Market Signals
Indicator
TXMD
FEMY
Relative Strength Index (RSI) 28.20 28.45
Support Level N/A $0.37
Resistance Level $2.16 $3.21
Average True Range (ATR) 0.07 0.19
MACD -0.01 -0.01
Stochastic Oscillator 16.13 7.34

Price Performance

Historical Comparison
TXMD
FEMY

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: